Selpercatinib Study for Advanced Cancer

This study is testing a new drug called selpercatinib for people with advanced solid tumors, including certain types of thyroid cancer. The study is open-label, meaning both doctors and participants know what treatment is given. It aims to find out if the drug is safe, how the body processes it, and if it can help shrink tumors.

Selpercatinib is taken by mouth, twice a day at a dose of 160 milligrams. The study has two parts: Phase 1, which is finished, and Phase 2, where more people are being enrolled. Participants must have cancer that has grown or can't be treated with regular methods. They should also have a specific change in their genes called RET.

• Length of Study: Participants will be followed for up to 5 years.
• Visits Needed: Regular check-ups and tests to monitor health and tumor size.
• Risks: Possible side effects include tiredness, nausea, and changes in heart rhythm.